Vir Biotechnology Announces Board and Executive Changes
Ticker: VIR · Form: 8-K · Filed: 2025-01-30T00:00:00.000Z
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Vir Bio shakes up board & exec pay. Big changes coming?
AI Summary
Vir Biotechnology, Inc. announced on January 24, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect the company's strategic direction and operational stability.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Registrant
- January 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1800 Owens Street, Suite 900, San Francisco, California 94158 (address) — Principal Executive Offices
- 415-906-4324 (phone_number) — Registrant's Telephone Number
FAQ
Who are the departing directors or officers?
The filing indicates the departure of certain officers and directors but does not name them specifically in the provided text.
Who are the newly elected directors?
The filing states that directors have been elected but does not provide their names in the provided text.
What specific changes were made to compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers but does not detail the specifics in the provided text.
When did these changes become effective?
The earliest event reported is dated January 24, 2025, and the date as of change is also January 24, 2025.
What is Vir Biotechnology's primary business?
Vir Biotechnology, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
From the Filing
0001628280-25-003073.txt : 20250130 0001628280-25-003073.hdr.sgml : 20250130 20250130075127 ACCESSION NUMBER: 0001628280-25-003073 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250124 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250130 DATE AS OF CHANGE: 20250130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 25571196 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 vir-20250124.htm 8-K vir-20250124 FALSE 0001706431 0001706431 2025-01-24 2025-01-24 0001706431 exch:XNAS 2025-01-24 2025-01-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 ________________________________________ Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) ________________________________________ Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 415 ) 906-4324 (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 24, 2025, Vir Biotechnology, Inc. (the “Company”) announced that Ann (Aine) M. Hanly, Ph.D., the Company’s Executive Vice President and Chief Technology Officer, will be leaving the Company on February 26, 2025. The Company has appointed Maninder Hora, Ph.D. to the role of Executive Vice President and Chief Technical Operations Officer, effective February 27, 2025, and Dr. Hora will assume D